Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Journey Medical (DERM) Change in Accured Expenses (2020 - 2025)

Journey Medical (DERM) has disclosed Change in Accured Expenses for 6 consecutive years, with -$1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Accured Expenses rose 70.2% year-over-year to -$1.4 million, compared with a TTM value of $5.2 million through Sep 2025, up 261.24%, and an annual FY2024 reading of -$2.9 million, down 404.05% over the prior year.
  • Change in Accured Expenses was -$1.4 million for Q3 2025 at Journey Medical, down from $5.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $14.3 million in Q2 2021 and bottomed at -$10.5 million in Q3 2021.
  • Average Change in Accured Expenses over 5 years is -$27421.1, with a median of -$82000.0 recorded in 2023.
  • The sharpest move saw Change in Accured Expenses tumbled 6440.0% in 2024, then soared 845.05% in 2025.
  • Year by year, Change in Accured Expenses stood at -$2.1 million in 2021, then skyrocketed by 175.89% to $1.6 million in 2022, then plummeted by 30.09% to $1.1 million in 2023, then rose by 26.29% to $1.4 million in 2024, then tumbled by 196.12% to -$1.4 million in 2025.
  • Business Quant data shows Change in Accured Expenses for DERM at -$1.4 million in Q3 2025, $5.2 million in Q2 2025, and -$23000.0 in Q1 2025.